Atara Biotherapeutics (ATRA) Share-based Compensation (2013 - 2026)

Atara Biotherapeutics has reported Share-based Compensation for 14 years, with the latest figure at $749000.0 in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 82.2% year-over-year to $749000.0; the trailing twelve-month figure through Mar 2026 stood at $6.3 million (down 72.42% YoY), and the FY2025 full-year result was $9.8 million, down 63.88% from the prior year.
• Share-based Compensation for Q1 2026 stood at $749000.0, down from $1.5 million in the prior quarter.
• The five-year high for Share-based Compensation was $14.3 million in Q1 2022, with the low at $749000.0 in Q1 2026.
• Historically, Share-based Compensation has averaged $8.0 million across 5 years, with a median of $8.4 million in 2024.
• Annual changes were most pronounced in 2022 — Share-based Compensation rose 16.85% — and 2026, when it slumped 82.2%.
• Atara Biotherapeutics' Share-based Compensation stood at $11.4 million in 2022, then dropped by 12.64% to $9.9 million in 2023, then tumbled by 41.11% to $5.8 million in 2024, then plunged by 74.05% to $1.5 million in 2025, then tumbled by 50.63% to $749000.0 in 2026.
• The last three Share-based Compensation figures came in at $749000.0 (Q1 2026), $1.5 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.